Now in its 52nd year, Tufts CSDD’s Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation equips drug developers, regulators, policymakers, clinical investigators, and researchers with the knowledge and skills for success in the life sciences sector. 🌟 What to Expect: · Insights from top speakers in industry, academia, and the FDA · A comprehensive overview of pharmaceutical development · A unique opportunity to network with thousands of alumni from around the globe 🎓 Whether you're new to the field or a seasoned professional, this course offers something for everyone. Plus, group rates are available for three or more colleagues. To learn more, email Sarah Wrobel, MHA at sarah.wrobel@tufts.edu 🔗 Learn more and register today: https://lnkd.in/gEgrCeg
Tufts Center for the Study of Drug Development
Pharmaceutical Manufacturing
Boston, Massachusetts 3,420 followers
An Independent, Academic, Non-profit Research Center at Tufts University School of Medicine in Boston, Massachusetts.
About us
Our Mission The Tufts Center for the Study of Drug Development is an independent, academic, non-profit research group at Tufts University in Boston, Massachusetts. Our mission is to develop strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical and biopharmaceutical development, review, and utilization. Our path-breaking research informs the research-based industry, regulatory agencies, and the public about the nature and pace of pharmaceutical development Our Objectives * To monitor and report on the development, regulation, and utilization of new drugs and biopharmaceuticals. * To explore the economic, legal, scientific, and public policy issues affecting pharmaceutical and biopharmaceutical innovation worldwide * To serve as an information resource on the development and regulation of new therapeutic agents. * To sponsor public forums and conferences that bring together the perspectives of government, industry, academia, and the public health community. * To raise the level of national and international debate on issues related to new drug and biopharmaceutical product development and regulation.
- Website
-
http://csdd.tufts.edu
External link for Tufts Center for the Study of Drug Development
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Nonprofit
- Founded
- 1976
Locations
-
Primary
145 Harrison Ave
Boston, Massachusetts 02111, US
Employees at Tufts Center for the Study of Drug Development
-
Ken Kaitin
Professor of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development
-
Zeid Barakat
-
Joan Chambers
Executive Leader: Strategic Relationships | Product & Brand Development | Financial Leadership | Strategic Planning & Execution | Marketing & Content…
-
Mark Bloomberg, MD, MBA, FACPE
Physician Executive; Expert in Healthcare Quality Improvement
Updates
-
Thank you to Pharma Focus Asia Magazine for highlighting this must-read article with Tufts CSDD Data Scientist Abigail Dirks, MS presenting a comprehensive assessment of risk-based quality management (RBQM) in clinical trials. Read the full article in Pharma Focus Asia, Magazine Issue 56: https://lnkd.in/gjymmJmM To explore more publications from CSDD, visit https://lnkd.in/evgdAAG9
𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐨𝐟 𝐑𝐢𝐬𝐤-𝐛𝐚𝐬𝐞𝐝 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 Abigail Dirks, MS, 𝐚 𝐝𝐚𝐭𝐚 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭 𝐚𝐭 𝐭𝐡𝐞 Tufts Center for the Study of Drug Development, presents a comprehensive assessment of risk-based quality management (RBQM) in clinical trials. As the FDA and EMA champion the adoption of risk-based monitoring, this article sheds light on adoption levels, barriers, and industry perceptions. Gain valuable insights into how RBQM can enhance the safety and efficacy of clinical trials, ensuring that essential data remains uncompromised. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐢𝐧 "𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚, 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞 𝟓𝟔": https://lnkd.in/g6QW-zFR 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/dxkGndFf 𝐒𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐛𝐲 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐢𝐧𝐠 𝐡𝐞𝐫𝐞: https://lnkd.in/ghDSEXKj 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞𝐬: https://lnkd.in/eBQD_FfQ 𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐚𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐦𝐞𝐝𝐢𝐚 𝐩𝐚𝐜𝐤 𝐡𝐞𝐫𝐞: https://lnkd.in/dbaBPC8E #ClinicalTrials #RiskManagement #RBQM #FDA #EMA #DataScience #DrugDevelopment #Pharmaceuticals #HealthcareInnovation #QualityManagement #ClinicalResearch #TuftsCenter #PharmaFocus #ResearchInsights
-
Joseph DiMasi, PhD, Director of Economic Analysis and Research Associate Professor at Tufts CSDD, has been named a Highly Ranked Scholar - Lifetime by ScholarGPS. Dr. DiMasi is ranked as the #1 scholar in drug development and is among the top 0.05 percent of all scholars for his lifetime contributions to the field of drug development. ScholarGPS is a website platform that ranks scholarly accomplishments while accounting for varying citation and publication patterns across different fields. The title of Highly Ranked Scholar is awarded to researchers in the top 0.05% across all disciplines. Congrats to Dr. DiMasi! To explore Dr. DiMasi's work, visit https://lnkd.in/evgdAAG9
-
The Inflation Reduction Act’s Drug Price Negotiation Program (DPNP) can do more than just implement pricing changes—it could significantly impact postapproval activities, especially in oncology. With a majority of FDA-approved indications and clinical trials occurring postapproval, oncology drugs face unique challenges under the new eligibility dates. Small molecules are particularly vulnerable, with more than double the exposure compared to biologics. 📊 For anyone in biopharma, this article is a must-read to understand the potential ripple effects on innovation and investment. Access the full article at https://lnkd.in/eE7hk2Gb #Oncology #DrugDevelopment #Pharma #Biotech #InflationReductionAct
-
Are you looking for original research, analysis, and insight into critical drug development issues and the clinical trials landscape? The Tufts CSDD bi-monthly publication provides all this cutting-edge information to help you stay informed about ongoing industry trends. Start your annual subscription today. Multi-reader programs are also available. Visit https://lnkd.in/dSYX898E or contact Joan Chambers at joan.chambers@tufts.edu
-
🌟 A big thank you to all our incredible colleagues in drug development who joined us at Tufts CSDD's Roundtable on Optimizing the Regulatory Submission Process on Monday! Your insights and contributions sparked a fruitful discussion that will pave the way for new developments in our research. It's evident that our progress relies on the active involvement of dedicated partners like you. We are looking forward to seeing you at the next event! Let’s keep the momentum going! 🚀 #DrugDevelopment #Collaboration #TuftsCSDD #RegulatoryScience
-
⭐ Tufts CSDD's October 2024 Insider is Here ⭐ Unlocking Integration: New Tufts CSDD Studies Underway, Plus Registration Opening for the 52nd Annual Postgraduate Course Click below to read this month's issue and subscribe to get future issues delivered directly to your inbox: https://lnkd.in/eWY5bnhn
-
Tufts Center for the Study of Drug Development reposted this
Are clinical trials leaving underserved communities behind? Research that excludes diverse populations can lead to biased treatment development and health disparities. That's why ensuring inclusivity and diversity in clinical trials is crucial for developing treatments that work for everyone. That's where decentralized clinical trials come in. DCTs leverage technology to offer remote and virtual options, making it more accessible for these communities to participate in clinical research. Want to learn more about how DCTs are revolutionizing clinical research? Check out this article: https://lnkd.in/dkeW23qY Let’s work together to create decentralized solutions that leave no patient behind. By embracing technology and innovation, we can ensure that everyone has equal access to life-changing clinical trials! #decentralized #clinicaltrials #healthcareinnovation
-
Despite the substantial advertising dollars spent annually, patient recruitment remains one of the most difficult challenges clinical research professionals encounter. Yesterday, Applied Clinical Trials Magazine published an article by 2024 Tufts CSDD intern Victoria Z. and Executive Director Ken Getz providing valuable insight on Trends in Patient Recruitment Advertising From 2012 to 2019. To read the full article, visit https://lnkd.in/e5t5UNYz
Despite the substantial advertising dollars spent annually, patient recruitment remains one of the most difficult challenges that clinical research professionals encounter🖋️Victoria Z. and Ken Getz, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
Trends in Patient Recruitment Advertising From 2012-2019
appliedclinicaltrialsonline.com
-
Grateful for the unwavering support of the Tufts CSDD Circle of Supporters. Your contributions, dedication, and feedback are crucial to advancing our mission. We invite more companies to join this dedicated group and help us shape the future of drug development and healthcare innovation. Together, we can make a difference. Join the Circle of Supporters today. Contact Joan Chambers, joan.chambers@tufts.edu for details and membership benefits.